» Articles » PMID: 8663011

The Proteinase-activated Receptor 2 is Induced by Inflammatory Mediators in Human Endothelial Cells. Comparison with the Thrombin Receptor

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1996 Jun 21
PMID 8663011
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

The proteinase-activated receptor 2 (PAR-2) belongs to the family of seven transmembrane region receptors, and, like the related thrombin receptor, it is activated by specific proteolytic cleavage of its extracellular amino terminus. It is not known which proteinase is the physiological activator of the PAR-2, but candidates can be found among the enzymes involved in the inflammatory cascade systems. Here, we have studied the effects of various mediators on the expression of the PAR-2 and the thrombin receptor in cultured human umbilical vein endothelial cells. Stimulation with the cytokines tumor necrosis factor alpha or interleukin-1 alpha as well as bacterial lipopolysaccharide elevated the expression of PAR-2 in a dose-dependent manner. The time course of induction after cytokine stimulation was similar to those published for the adhesion molecules intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. After 20 h of stimulation, PAR-2 mRNA and protein levels were increased to 5-10-fold basal values, and, in the continued presence of tumor necrosis factor alpha, PAR-2 mRNA expression was found to remain elevated for up to 4 days. In contrast, the thrombin receptor gene was not induced by any of these inflammatory mediators. The responses to phorbol ester treatment also differed between the two genes. Thrombin receptor mRNA levels decreased steadily up to 20 h, whereas PAR-2 mRNA levels first rose to about 3-fold basal values at 4 h before decreasing again. Cell surface protein levels of both receptors were decreased after 20 h of phorbol ester stimulation. Elevating intracellular cAMP levels by treatment with forskolin resulted in decreased expression of both receptors, and inhibition of cAMP degradation appeared to blunt the cytokine-induced increase in PAR-2 expression. The induction of the PAR-2 by cytokine treatment supports the concept of PAR-2 involvement in the acute inflammatory response.

Citing Articles

Protease-activated receptors in vascular smooth muscle cells: a bridge between thrombo-inflammation and vascular remodelling.

Habibi A, Ruf W, Schurgers L Cell Commun Signal. 2025; 23(1):57.

PMID: 39891111 PMC: 11786455. DOI: 10.1186/s12964-025-02066-6.


Protease activated receptor 2 as a novel druggable target for the treatment of metabolic dysfunction-associated fatty liver disease and cancer.

Villano G, Pontisso P Front Immunol. 2024; 15:1397441.

PMID: 39464875 PMC: 11502361. DOI: 10.3389/fimmu.2024.1397441.


Comparative Cardioprotective Effectiveness: NOACs vs. Nattokinase-Bridging Basic Research to Clinical Findings.

Muric M, Nikolic M, Todorovic A, Jakovljevic V, Vucicevic K Biomolecules. 2024; 14(8).

PMID: 39199344 PMC: 11352257. DOI: 10.3390/biom14080956.


Xa inhibitor edoxaban ameliorates hepatic ischemia-reperfusion injury via PAR-2-ERK 1/2 pathway.

Maeda K, Kuriyama N, Noguchi D, Ito T, Gyoten K, Hayasaki A PLoS One. 2024; 19(5):e0292628.

PMID: 38748746 PMC: 11095713. DOI: 10.1371/journal.pone.0292628.


Protease-activated receptor-2: Role in asthma pathogenesis and utility as a biomarker of disease severity.

Gandhi V, Palikhe N, Vliagoftis H Front Med (Lausanne). 2022; 9:954990.

PMID: 35966869 PMC: 9372307. DOI: 10.3389/fmed.2022.954990.